EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Impact of FCGR2A and FCGR3A Gene Variants on the Response to Rituximab in Patients With Glomerular Diseases

María Larrosa-García iD, Irene Agraz Pamplona, Susana Rojo Tolosa iD, Alberto Jiménez Morales, María Teresa Sanz Martínez, Mónica Martínez Gallo, Roger Colobran, Helena Genestal Vicente, Nerea Moreno Pena, Roxana Paola Bury Macías, José Bruno Montoro Ronsano

Pharmacology Research & Perspectives · 2026-06 · 14 (3)

DOI: 10.1002/prp2.70261 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, online erschienen am 22.05.2026. Verfasst von María Larrosa-García und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacy Service, Vall D'hebron Hospital Campus, Barcelona, Spain. Hauptthemen laut MEDLINE: Receptors, IgG, Rituximab, Immunologic Factors. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Societat Catalana de Farmacai Clínica.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rituximab is an anti‐CD20 monoclonal antibody used in autoimmune diseases, including glomerular diseases. The FCGR2A (rs1801274) and FCGR3A (rs396991) variants have been suggested to affect rituximab efficacy; this study evaluates their impact on rituximab efficacy in glomerular diseases. A clinical trial was performed including adults with glomerular diseases who required rituximab (NEFRTX; EudraCT: 2020–000484‐23). Patients received 1.0 g or 0.5 g of rituximab on day 1 (± day 14); biochemical parameters and rituximab concentration were measured, and FCGR2A and FCGR3A variants were characterized. Clinical outcome was evaluated at 6 and 12 months. 30 patients were included. FCGR2A (rs1801274) and FCGR3A (rs396991) variants did not show an effect on clinical response to rituximab. When the effect of the variant was corrected by rituximab exposure, the expression of the FCGR2A rs1801274‐A allele vs. no expression was related to a poorer response at month 6 (odds ratio 0.034; 95% confidence interval 0.002–0.725; p = 0.030); this effect was not seen for FCGR3A . Additional studies involving larger cohorts are warranted to validate these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, IgGRituximabImmunologic FactorsHumansFemaleMaleMiddle AgedAgedTreatment OutcomeAdultPolymorphism, Single Nucleotide

Stichwörter der Autor:innen

FCGR2AFCGR3Apharmacogeneticsrituximab

Substanzen

Receptors, IgGRituximabFCGR3A protein, humanFCGR2A protein, humanImmunologic Factors

Autor:innen und Institutionen

  • Clinical Pharmacy Service, Vall D'hebron Hospital Campus, Barcelona, Spain.
  • Vall D'hebron Institute of Research, Barcelona, Spain.
  • Clinical Nephrology Service, Vall D'hebron Hospital Campus, Barcelona, Spain.
  • Pharmacogenetics Unit. Hospital Universitario Virgen de Las Nieves, Granada, Spain.
  • Clinical Pharmacy Service, Hospital Universitario Virgen de Las Nieves, Granada, Spain.
  • Immunology Division, Vall D'hebron Barcelona Hospital Campus, Barcelona, Spain.

ORCID-Profile: María Larrosa-García, Susana Rojo Tolosa

Förderung

  • Societat Catalana de Farmacai Clínica

Zitieren

APA

Larrosa-García, M., Pamplona, I. A., Tolosa, S. R., Morales, A. J., Martínez, M. T. S., Gallo, M. M., Colobran, R., Vicente, H. G., Pena, N. M., Macías, R. P. B., & Ronsano, J. B. M. (2026). Impact of FCGR2A and FCGR3A Gene Variants on the Response to Rituximab in Patients With Glomerular Diseases. Pharmacology Research & Perspectives, 14(3). https://doi.org/10.1002/prp2.70261

Vancouver

Larrosa-García M, Pamplona IA, Tolosa SR, Morales AJ, Martínez MTS, Gallo MM, et al. Impact of FCGR2A and FCGR3A Gene Variants on the Response to Rituximab in Patients With Glomerular Diseases. Pharmacology Research & Perspectives. 2026;14(3). doi:10.1002/prp2.70261

BibTeX
@article{LarrosaGarca2026,
  author = {Larrosa-García, María and Pamplona, Irene Agraz and Tolosa, Susana Rojo and Morales, Alberto Jiménez and Martínez, María Teresa Sanz and Gallo, Mónica Martínez and Colobran, Roger and Vicente, Helena Genestal and Pena, Nerea Moreno and Macías, Roxana Paola Bury and Ronsano, José Bruno Montoro},
  title = {Impact of FCGR2A and FCGR3A Gene Variants on the Response to Rituximab in Patients With Glomerular Diseases},
  journal = {Pharmacology Research & Perspectives},
  year = {2026},
  volume = {14},
  number = {3},
  doi = {10.1002/prp2.70261}
}
Kostenlos starten →